Principal Financial Group
CASI

Principal Financial Group’s CASI Pharmaceuticals CASI Stock Holding History

Principal Financial Group’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,256
Closed -$30K – 2607
2021
Q1 		$30K Sell
1,256
-185
-13% -$5.2K ﹤0.01% 2471
2020
Q4 		$43K Buy
+1,441
New +$31.3K ﹤0.01% 2399

Other funds holding CASI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Principal Financial Group's CASI Position: Q2 2021 in Review

Principal Financial Group sold out of CASI Pharmaceuticals (CASI) in Q2 2021, closing a stake of 1,256 shares — an estimated $30K sold.

Principal Financial Group first reported a position in CASI in Q4 2020 and held it in 2 quarters. The position peaked at $43K in Q4 2020. 68 funds tracked by Wall St. Rank hold CASI as of Q2 2021.

  • Principal Financial Group reported no remaining CASI Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Principal Financial Group sold 1,256 CASI Pharmaceuticals shares in Q2 2021, an estimated $30K.
  • Principal Financial Group first reported a position in CASI Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Principal Financial Group's CASI Pharmaceuticals position peaked at $43K in Q4 2020.
  • 68 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q2 2021.

Based on Principal Financial Group's 13F filing for Q2 2021, filed 10 Aug 2021.